174 related articles for article (PubMed ID: 24948077)
1. HMG-CoA reductase inhibitors pravastatin, lovastatin and simvastatin suppress delayed rectifier K(+)-channel currents in murine thymocytes.
Kazama I; Baba A; Maruyama Y
Pharmacol Rep; 2014 Aug; 66(4):712-7. PubMed ID: 24948077
[TBL] [Abstract][Full Text] [Related]
2. Benidipine persistently inhibits delayed rectifier K(+)-channel currents in murine thymocytes.
Kazama I; Maruyama Y; Matsubara M
Immunopharmacol Immunotoxicol; 2013 Feb; 35(1):28-33. PubMed ID: 22978806
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of clarithromycin and azithromycin on delayed rectifier K(+)-channel currents in murine thymocytes.
Kazama I; Maruyama Y
Pharm Biol; 2013 Jun; 51(6):760-5. PubMed ID: 23527897
[TBL] [Abstract][Full Text] [Related]
4. Suppressive effects of diltiazem and verapamil on delayed rectifier K(+)-channel currents in murine thymocytes.
Baba A; Tachi M; Maruyama Y; Kazama I
Pharmacol Rep; 2015 Oct; 67(5):959-64. PubMed ID: 26398391
[TBL] [Abstract][Full Text] [Related]
5. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
[TBL] [Abstract][Full Text] [Related]
6. Suppressive effects of nonsteroidal anti-inflammatory drugs diclofenac sodium, salicylate and indomethacin on delayed rectifier K+-channel currents in murine thymocytes.
Kazama I; Maruyama Y; Murata Y
Immunopharmacol Immunotoxicol; 2012 Oct; 34(5):874-8. PubMed ID: 22409730
[TBL] [Abstract][Full Text] [Related]
7. Voltage-dependent biphasic effects of chloroquine on delayed rectifier K(+)-channel currents in murine thymocytes.
Kazama I; Maruyama Y; Murata Y; Sano M
J Physiol Sci; 2012 May; 62(3):267-74. PubMed ID: 22328488
[TBL] [Abstract][Full Text] [Related]
8. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
9. Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells.
Oi S; Haneda T; Osaki J; Kashiwagi Y; Nakamura Y; Kawabe J; Kikuchi K
Eur J Pharmacol; 1999 Jul; 376(1-2):139-48. PubMed ID: 10440099
[TBL] [Abstract][Full Text] [Related]
10. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
[TBL] [Abstract][Full Text] [Related]
11. Second-Generation Histamine H1 Receptor Antagonists Suppress Delayed Rectifier K
Saito K; Abe N; Toyama H; Ejima Y; Yamauchi M; Mushiake H; Kazama I
Biomed Res Int; 2019; 2019():6261951. PubMed ID: 31183371
[TBL] [Abstract][Full Text] [Related]
12. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
[TBL] [Abstract][Full Text] [Related]
13. Simvastatin and lovastatin, but not pravastatin, interact with MDR1.
Sakaeda T; Takara K; Kakumoto M; Ohmoto N; Nakamura T; Iwaki K; Tanigawara Y; Okumura K
J Pharm Pharmacol; 2002 Mar; 54(3):419-23. PubMed ID: 11902809
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.
Yada T; Nakata M; Shiraishi T; Kakei M
Br J Pharmacol; 1999 Mar; 126(5):1205-13. PubMed ID: 10205010
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
16. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors.
Newman A; Clutterbuck RD; Powles RL; Catovsky D; Millar JL
Leuk Lymphoma; 1997 Feb; 24(5-6):533-7. PubMed ID: 9086443
[TBL] [Abstract][Full Text] [Related]
17. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors.
Yang SH; Choi JS; Choi DH
Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429
[TBL] [Abstract][Full Text] [Related]
18. Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin.
Serajuddin AT; Ranadive SA; Mahoney EM
J Pharm Sci; 1991 Sep; 80(9):830-4. PubMed ID: 1800703
[TBL] [Abstract][Full Text] [Related]
19. HMG-CoA reductase activity in human liver microsomes: comparative inhibition by statins.
Dansette PM; Jaoen M; Pons C
Exp Toxicol Pathol; 2000 May; 52(2):145-8. PubMed ID: 10965989
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
